Biophytis to Restate Previously Issued Financial Statements Biophytis today announced that the Company’s previously issued audited consolidated financial statements for the fiscal years ended December 31, 2019 and 2020 and unaudited consolidated financial statements for the six month periods ended June 30, 2021 and 2020 will be restated to correct the Company’s accounting treatment of…
Biophytis to host virtual KOL event on Sarconeos (BIO101) on its lead projects in COVID-19 and Sarcopenia Biophytis today announces it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia. The webinar will feature a presentation by four…
Biophytis announces the drawing of 2 new tranches of ORNANE under the 2020 Atlas Contract for €6 million Biophytis today announces the issuance of 240 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €6 million under its existing convertible bond agreement with Atlas, a specialized investment fund based…
Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021 Biophytis today announces the full results from the SARA-INT Phase 2 trial of Sarconeos (BIO101) in Sarcopenia that have been presented…
Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021 Biophytis today announces it will present full results from the SARA-INT Phase 2 trial of Sarconeos (BIO101) in Sarcopenia at the…
Stanislas Veillet tells us in video on the active preparation of the marketing of Sarconeos for the first half of 2022
Biophytis publishes its interim financial report for the first half of 2021 and provides updates on key operational developments and financing transactions SARA-INT: Positive top line results of Phase 2 study demonstrate efficacy of Sarconeos (BIO101) in sarcopenia and support progress into Phase 3 COVA: DMC second interim analysis shows efficacy results in the promising…
Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19 Biophytis today announces the recommendation by the Data Monitoring Committee (DMC) to continue the Phase 2-3 COVA study without any modification of the protocol, after the interim efficacy data were found…
Biophytis announces its management will participate and meet with investors at the following upcoming events and conferences: H. C. Wainwright 23rd Annual Global Investment ConferenceSeptember 13 to 15 – Virtual Amsterdam MidCap EventSeptember 20 to 21 – Virtual Investor Access EventSeptember 27 to 28 – Paris HealthTech Innovation DaysOctober 4 to 5 – Paris European…
SAVE THE DATE THURSAY, SEPTEMBER 30 • ROUNDTABLE 9:00-9:30 AM USA (EST) TIME SARA results will be presented and discussed, in a dedicated session, during the next ICFSR congress SARCONEOS BIO101 IN SARCOPENIA: LESSONS LEARNED FROM THE SARA PROGRAM Biophytis experts : Cendrine Tourette, PhD – Waly Dioh, PhD – Jean Mariani, with the presence…